Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Dec 22, 2022
Dec 21, 2022
Dec 15, 2022
Events
Mar 28 - Apr 1, 2023
Jan 9, 2023 at 8:00 AM PST
Jan 8, 2023
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
10-K | Annual report which provides a comprehensive overview of the company for the past year |
|
10-Q | Quarterly report which provides a continuing view of a company's financial position |
|
10-Q | Quarterly report which provides a continuing view of a company's financial position |